Avivagen Inc. (VIVXF)
Avivagen Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Ottawa, ON, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $7,769. On trailing twelve-month figures it carries a trailing P/E of -0.11, a net margin of -645.9%. Its beta of 0.35 implies it has historically moved less than the broad market.
Avivagen Inc. is a life sciences enterprise that invents and sells specialized products, primarily for animal feed, aimed at bolstering the immune systems of livestock. These solutions are designed to enhance animals' health, leading to improved growth and overall productivity. The company's diverse product lineup features OxC-beta Livestock, a crucial premix for farm animal diets. Beyond agriculture, Avivagen also manufactures health supplements such as Vivamune and Dr. Tobias-branded chews for dogs, along with the Dr. Tobias Beta blend, formulated to support human immunity. Established in 2005 and based in Ottawa, Canada, Avivagen Inc. distributes its offerings across numerous international markets, including the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia.
Avivagen Inc. is most often compared with the following Healthcare names: